Docetaxel-induced nail dystrophy

Australasian Journal of Dermatology

Volumn 43, Issue 4, 2002, Pages 293-296

  Nicolopoulos, Jenny ^a   Howard, Anne ^a  

^a NONE   (Australia)

Author keywords

Onycholysis; Onychophosis; Taxanes

Indexed keywords

DOCETAXEL; FLUCLOXACILLIN; GOSERELIN; ONDANSETRON; PREDNISOLONE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; FINGER NAIL; HUMAN; INDEX FINGER; MALE; METASTASIS; NAIL BED; NAIL DISEASE; NAIL DYSTROPHY; ONYCHOLYSIS; ONYCHOPHOSIS; PARONYCHIA; PROSTATE CANCER; THUMB; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; NAIL DISEASES; PACLITAXEL; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 0036439371     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2002.00616.x     Document Type: Article

References (27)

1. Crown J, O'Leary M. The taxanes: An update. Lancet 2000; 355: 1176-8.
2. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy 1997; 17: 96S-104S.
3. Llombart-Cussac A, Pivot X, Spielmann M. Docetaxel chemotherapy induces transverse superficial loss of the nail plate. Arch. Dermatol. 1997; 133: 1466-7.
4. Jacob CI, Patten SF. Nail bed dyschromia secondary to docetaxel therapy. Arch. Dermatol. 1998; 134: 1167-8.
5. Obermair A, Binder M, Barrada D, Bancher-Todesca D, Asseryanis E, Kubista E. Onycholysis in patients treated with docetaxel. Ann. Oncol. 1998; 9: 230-1.
6. Wasner G, Hilpert F, Baron R, Pfisterer J. Nail changes secondary to docetaxel. Lancet 2001; 357: 910.
7. Slee PHTJ. Nail changes after chemotherapy. N. Engl. J. Med. 1997; 337: 168.
8. Vanhooteghem O, Andre J, Vindevoghel A, Vandenbossche L, Vandeveire A, Song M. Docetaxel-induced subungual haemorrhage. Dermatology 1997; 194: 419-20.
9. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J. Nail changes secondary to docetaxel (Taxotere). Dermatology 1999; 198: 288-90.
10. Vanhooteghem O, Richert B, Vindevoghel A, Vandenbossche L, Vandeveire A, De La Brassinne M. Subungual abscess: A new ungual side-effect related to docetaxel therapy. Br. J. Dermatol. 2000; 143: 462-3.
11. Kaye SB. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin. Oncol. 1995; 22 (Suppl. 4): 30-3.
12. Cortes JE, Pazdur R. Docetaxel. J. Clin. Oncol. 1995; 13: 2643-55.
13. Trudeau ME. Docetaxel: A review of its pharmacology and clinical activity. Can. J. Oncol. 1996; 6: 443-57.
14. Sparreboom A, Van Telligen O, Nooijen WJ, Beijenen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998; 9: 1-17.
15. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention. J. Clin. Oncol. 1997; 15: 3149-55.
16. Correia O, Azevedo R, Begonha R, Vasconcelos A, Braga-Cruz F, Polonia J. Skin adverse reactions to docetaxel (Taxotere). Australas. J. Dermatol. 1997; 38 (Suppl. 2): 282-3.
17. Battafarano DF, Zimmerman GC, Older SA, Keeling JH, Burris HA. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995; 76: 110-15.
18. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: Characterisation by histopathology and clinical course. J. Natl Cancer Inst. 1994; 86: 51-3.
19. Weinberg JM, Egan CL, Tangoren A, Li U, Langhinghouse KA, Guzzo CA. Generalised pustular dermatosis following paclitaxel therapy. Int. J. Dermatol. 1997; 36: 313-14.
20. Young PC, Montemarano AD, Lee N, Sau P, Weiss RB, James WD. Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. J. Am. Acad. Dermatol. 1996; 34: 313-14.
21. Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel: Establishment of a prerequisite radiation threshold. Eur. J. Cancer 1997; 33: 698-9.
22. Trudeau ME. Docetaxel (Taxotere): An overview of first-line monotherapy. Semin. Oncol. 1995; 22: 17-21.
23. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy: Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000; 88: 2367-71.
24. Almagro M, Del Pozo J, Garcia-Silva J, Vazquez A, Fonseca E. Nail alterations secondary to paclitaxel therapy. Eur. J. Dermatol. 2000; 10: 146-7.
25. Flory SM, Solimando DA, Webster GF, Dunton CJ, Neufeld JM, Haffey MB. Onycholysis associated with weekly administration of paclitaxel. Ann. Pharmacother. 1999; 33: 584-6.
26. Luftner D, Flath B, Akrivakis C, Schwegert M, Prinz B, Mergenthaler HG, Petrides PE, Wernecke KD, Possinger K. Dose-intensified weekly paclitaxel induces multiple nail disorders. Ann. Oncol. 1998; 9: 1139-41.
27. Huinink WWB, Prove AM, Piccart M, Steward W, Wanders J, Franklin H et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann. Oncol. 1994; 5: 527-32.